Relationship between histologic grade and cytofluorometric cellular DNA and RNA content in primary bone tumors.
The diagnosis and grading of bone tumors remains a challenging problem. We studied the relationship between histologic grade and cytofluorometric cellular DNA and RNA content in 108 primary bone tumors. The data included DNA ploidy, mean DNA content (MDC), S-phase fraction (SPF), mean RNA content (MRC) and RNA/DNA ratio (RDR; MRC/MDC) which represents the RNA content normalized for the DNA content. Benign tumors had a diploid stem line with low MDC (mean; 1.04), low SPF (0.9), high MRC (2.41) and high RDR (2.31). Giant cell tumors of bone, which are locally aggressive benign tumors, showed diploidy with relatively higher MDC (1.07, p < 0.01) and SPF (2.6, p < 0.01) and lower MRC (1.81, p < 0.01) and RDR (1.69, p < 0.01). Similar results were obtained in low-grade sarcomas. In high-grade sarcomas, the data depended on the histologic findings. Pleomorphic sarcomas such as osteosarcomas revealed aneuploidy with remarkably higher MDC (1.70 in osteosarcomas, p < 0.01) and SPF (6.5, p < 0.01), but lower RDR (1.70, p < 0.01). In contrast, small cell sarcomas, such as Ewing's sarcomas, showed diploidy with low MDC (1.11 in Ewing's sarcomas, N.S.) and SPF (2.5, p < 0.01) and extremely low RDR (1.34, p < 0.01). The RDR value was higher in well-differentiated tumors than in primitive tumors, rendering it useful in grading bone tumors with a diploid stem line. By combining the RDR value with the MDC value, 96% of diploid sarcomas could be distinguished from benign tumors. These results indicate that cellular DNA and RNA content analysis may be of value in assessing the malignant potential of diploid as well as aneuploid bone sarcomas.
Takeshita
H
H
Department of Orthopaedic Surgery, Kyoto Prefectural University of Medicine, Kyoto 602, Japan.
Kusuzaki
K
K
Kuzuhara
A
A
Tsuji
Y
Y
Ashihara
T
T
Gebhardt
M C
MC
Mankin
H J
HJ
Springfield
D S
DS
Hirasawa
Y
Y
D001859:Bone Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology; D004273:DNA, Neoplasm / Q000032:analysis*; D004171:Diploidy; D005434:Flow Cytometry / Q000379:methods; D018212:Giant Cell Tumor of Bone / Q000145:classification / Q000235:genetics / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000145:classification / Q000235:genetics / Q000473:pathology; D012334:RNA, Neoplasm / Q000032:analysis*
D004273:DNA, Neoplasm; D012334:RNA, Neoplasm